Overview

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD

Phase:

Phase 3

Details

Lead Sponsor:

CSL Behring

Collaborators:

Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Treatments:

Alpha 1-Antitrypsin
Protease Inhibitors
Protein C Inhibitor